Hence, incorporating CAR19 or other CARs targeting B cell lineage markers (see below) onto DNTs may provide an alternate treatment that is safe, accessible, and a potent off-the-shelf-ACT against CD19+ B-ALL. Here, CD19 is linked to acute lymphoblastic leukemia.